Under the terms of the settlement, the New Jersey-based company would provide $92.5 million in cash and $180 million worth of naloxone nasal sprays to treat overdoses.
The settlement in principle accounts for New Jersey-based Amneal's role in fueling the national epidemic of opioid addictions and overdoses, New York and California said in separate statements.
Good morning, and welcome to the Amneal Pharmaceuticals First Quarter 2024 Earnings Call. I will now turn the call over to Amneal's Head of Investor Relations, Tony Dimeo.
BRIDGEWATER, N.J. (AP) — BRIDGEWATER, N.J. (AP) — Amneal Pharmaceuticals, Inc. (AMRX) on Friday reported a loss of $91.6 million in its first quarter. On a per-share basis, the Bridgewater, New ...